VCCRI: 'Heart in a Box'

An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.

VCCRI: 'Heart in a Box'

September 6, 2022
An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.
Read Transcript

An Australian method of preserving donated hearts has boosted the number of successful transplants and new data shows recipients of these “dead” tickers have similar survival rates to traditional transplants.

There have been 78 heart transplants conducted through Sydney’s St Vincent’s Hospital and the Victor Chang Cardiac Research Institute’s world-first DCD (donation after circulatory death) process, a technique that has since been adopted by several hospitals abroad.

While donated hearts once had to come from brain-dead people whose hearts were still beating, the DCD method, pioneered in Sydney, means donations can take place after the heart has stopped. Within half an hour of life support being switched off, the heart is extracted and flushed with an oxygenated blood preservation solution before being transported in a special machine to its recipient.

“These are hearts that would not otherwise have been used,” said Professor Peter MacDonald, a senior cardiologist at St Vincent’s Hospital and leader of the DCD heart transplant team.

When Sydneysider Ross Tripodi woke up from his DCD heart transplant in April 2020, he assumed it must not have happened: he didn’t feel like he had just had a big surgery, he felt better than before.

“I was bright-eyed and bushy-tailed,” the 57-year-old recalled. “I turned to the nurse and said, ‘Oh, you haven’t done the transplant?’”

Tripodi was diagnosed with cardiomyopathy – an enlarged heart – aged 49. In 2019, experiencing organ failure, he was warned he would not survive another year without a transplant.

“I got home to see my daughter turn 21, most people take that for granted, but, for me, it was a lot,” he said. “There’s never a bad day anymore. You don’t sweat the little things. I’m just grateful for anything.”

A review of the first eight years of the program, published in the journal Transplantation, showed the new technology had increased the number of transplants performed at the hospital by 25 per cent.

It also demonstrated, in its small sample of 74 transplants, a negligible difference in one-year and five-year survival rates between people who received a heart via either method.

The review’s lead author Dr Yashutosh Joshi said it demonstrated there was “no reason why we shouldn’t” pursue DCD when appropriate for the patient. The five-year survival rate for a DCD heart transplant was 88 per cent, compared with 81 per cent for a brain-dead transplant.

“We don’t want to overstate the benefits of DCD over brain death because it’s still a small sample,” MacDonald said, noting heart transplant was generally a very successful procedure.

The newer method also comes with a time pressure that does not exist in traditional heart transplants. Joshi – who has travelled to collect donated hearts from as far as Darwin – described the program as “essentially 24/7”, with minutes saved by harvesting the organ in an anaesthetic bay, as opposed to in intensive care, contributing to success.

But, said Dr Emily Granger, a surgeon at St Vincent’s, the hearts donated through the DCD system are generally of better quality.

“When someone is brain-dead they have often had a surge of adrenaline which impacts the heart, but in these people their heart is in much better condition,” said Granger, who is also the president-elect of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.

At St Vincent’s, the only Australian hospital using the method, DCD procedures now account for 30 per cent of heart transplants. In the UK, where DCD transplants started in 2015, they account for almost half of procedures.

Hospitals in the US, Spain, Belgium and the Netherlands have also adopted the technology.

MacDonald said he expected the cost of the “heart in a box” – about $50,000 per use – would mean that it would probably never make up the majority of transplants, but it was an important way to increase organ donation.

The Organ and Tissue Authority’s national medical director, Associate Professor Helen Opdam, agreed, noting the pandemic had impacted the number of available donors and people receiving transplants.

“Heart transplantation from donation after circulatory death enables more people to have their wishes to donate honoured, as it has expanded the situations in which donation is possible,” she said. “It also means more people will have the chance to receive a life-saving heart transplant.”

St Vincent’s and the Victor Chang Cardiac Research Institute are now working with researchers at the University of Queensland to improve the viability of donated hearts, through a novel project involving the use of protein from funnel web spider venom in the preservation process.

 This article was originally posted by The Sydney Morning Herald here.

Licensed by Copyright Agency. You must not copy this work without permission.

An Australian method of preserving donated hearts has boosted the number of successful transplants and new data shows recipients of these “dead” tickers have similar survival rates to traditional transplants.

There have been 78 heart transplants conducted through Sydney’s St Vincent’s Hospital and the Victor Chang Cardiac Research Institute’s world-first DCD (donation after circulatory death) process, a technique that has since been adopted by several hospitals abroad.

While donated hearts once had to come from brain-dead people whose hearts were still beating, the DCD method, pioneered in Sydney, means donations can take place after the heart has stopped. Within half an hour of life support being switched off, the heart is extracted and flushed with an oxygenated blood preservation solution before being transported in a special machine to its recipient.

“These are hearts that would not otherwise have been used,” said Professor Peter MacDonald, a senior cardiologist at St Vincent’s Hospital and leader of the DCD heart transplant team.

When Sydneysider Ross Tripodi woke up from his DCD heart transplant in April 2020, he assumed it must not have happened: he didn’t feel like he had just had a big surgery, he felt better than before.

“I was bright-eyed and bushy-tailed,” the 57-year-old recalled. “I turned to the nurse and said, ‘Oh, you haven’t done the transplant?’”

Tripodi was diagnosed with cardiomyopathy – an enlarged heart – aged 49. In 2019, experiencing organ failure, he was warned he would not survive another year without a transplant.

“I got home to see my daughter turn 21, most people take that for granted, but, for me, it was a lot,” he said. “There’s never a bad day anymore. You don’t sweat the little things. I’m just grateful for anything.”

A review of the first eight years of the program, published in the journal Transplantation, showed the new technology had increased the number of transplants performed at the hospital by 25 per cent.

It also demonstrated, in its small sample of 74 transplants, a negligible difference in one-year and five-year survival rates between people who received a heart via either method.

The review’s lead author Dr Yashutosh Joshi said it demonstrated there was “no reason why we shouldn’t” pursue DCD when appropriate for the patient. The five-year survival rate for a DCD heart transplant was 88 per cent, compared with 81 per cent for a brain-dead transplant.

“We don’t want to overstate the benefits of DCD over brain death because it’s still a small sample,” MacDonald said, noting heart transplant was generally a very successful procedure.

The newer method also comes with a time pressure that does not exist in traditional heart transplants. Joshi – who has travelled to collect donated hearts from as far as Darwin – described the program as “essentially 24/7”, with minutes saved by harvesting the organ in an anaesthetic bay, as opposed to in intensive care, contributing to success.

But, said Dr Emily Granger, a surgeon at St Vincent’s, the hearts donated through the DCD system are generally of better quality.

“When someone is brain-dead they have often had a surge of adrenaline which impacts the heart, but in these people their heart is in much better condition,” said Granger, who is also the president-elect of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.

At St Vincent’s, the only Australian hospital using the method, DCD procedures now account for 30 per cent of heart transplants. In the UK, where DCD transplants started in 2015, they account for almost half of procedures.

Hospitals in the US, Spain, Belgium and the Netherlands have also adopted the technology.

MacDonald said he expected the cost of the “heart in a box” – about $50,000 per use – would mean that it would probably never make up the majority of transplants, but it was an important way to increase organ donation.

The Organ and Tissue Authority’s national medical director, Associate Professor Helen Opdam, agreed, noting the pandemic had impacted the number of available donors and people receiving transplants.

“Heart transplantation from donation after circulatory death enables more people to have their wishes to donate honoured, as it has expanded the situations in which donation is possible,” she said. “It also means more people will have the chance to receive a life-saving heart transplant.”

St Vincent’s and the Victor Chang Cardiac Research Institute are now working with researchers at the University of Queensland to improve the viability of donated hearts, through a novel project involving the use of protein from funnel web spider venom in the preservation process.

 This article was originally posted by The Sydney Morning Herald here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Sydney Morning Herald, published on Sep 06, 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
February 14, 2023

Bringing Equity and Diversity to Genomic Medicine

Professor Daniel MacArthur, Director of the Centre for Population Genomics has big goals to bring equity and diversity into genomic medicine in Australia, something surprisingly inadequate presently.

Read More
October 21, 2022

WEHI: Art of Science Online Exhibition 2022

WEHI has officially opened their interactive online exhibition, Art of Science, which features incredible biomedical images from WEHI researchers.

Read More
October 20, 2022

PMRI: Digital Education Platform Project - Pain Management

PMRI is developing digital pain education to support the emerging, current and future health workforce and improve the lives of patients with chronic pain.

Read More
September 16, 2022

Talking Tech: Matt Berriman, Founder of RealVC

Matt Berriman, founder of RealVC and ‘The Business of Sport’ panellist at 2022 Sohn Hearts & Minds Conference discusses his entrepreneurial learnings and the parallels between sports and business.

Read More
September 1, 2022

WEHI: Say Hi to the life-saving impact of medical research discoveries

HM1 beneficiary Walter and Eliza Hall Institute recently released a video dedicated to the life-saving impact of long-term medical research discoveries.

Read More
August 24, 2022

Cerebral Palsy Alliance: Changing the GAME

A research team at Cerebral Palsy Alliance is working to develop a world-first, early-intervention therapy approach for infants with cerebral palsy called ‘GAME’ (Goals, Activity, Motor Enrichment).

Read More
August 3, 2022

The Florey: New target in MND drug discovery

The Florey investigates how a previously underappreciated cell type potentially contributes to the progressive loss of motor neurons in Motor Neurone Disease (MND).

Read More
July 21, 2022

Remarkable Demo Day 2022: Disability-tech accelerator

Remarkable, Australia’s first disability-tech accelerator made possible by Cerebral Palsy Alliance, has released a video sharing the innovative products developed by the 2022 cohort.

Read More
July 11, 2022

Black Dog: Space 22

Black Dog Institute’s art-based researcher Professor Katherine Boydell is starring in an ABC documentary series, Space 22, hosted by Natalie Bassingthwaighte. The series follows those with lived experience of mental ill health.

Read More
June 21, 2022

WEHI: New findings could lead to cancer therapy without harmful side-effects

Researchers at WEHI have developed a way to potentially reduce the toxic side-effects of a type of immunotherapy, in findings that could overcome the pioneering treatment’s biggest limitation.

Read More
March 17, 2022

Victor Chang: Innovation Centre

COVID-19 may have stopped tours of Victor Chang's Innovation Centre but it certainly hasn’t slowed their scientists from making new discoveries as shown in this video with Sky News Australia.

Read More
February 24, 2022

Impact Video: Cerebral Palsy Alliance

This video features Professor Nadia Badawi AM, Professor Alistair McEwan, Paul Rayson and others discussing the incredible impact our partnership will have.

Read More
February 24, 2022

New Partnership with Cerebral Palsy Alliance

We’re excited to announce a new partnership with the Cerebral Palsy Alliance and are proud to be supporting this important research.

Read More
February 20, 2022

The Florey: What is 'Zoom Fatigue' and how to avoid it

The Florey has recently published new research that sheds light on the phenomenon of “zoom fatigue” – yes it’s a real thing! Listen to this podcast episode as Professor Bernhardt explains what it is and how to prevent it.

Read More
September 23, 2021

Partnership with Swinburne & Cooper Investors

Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.

Read More